Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Li-Fraumeni Syndrome × Specimen Handling × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Lung Neoplasms 67 Prostatic Neoplasms 63 Leukemia, Myeloid, Acute 56 Carcinoma, Non-Small-Cell Lung 54 Neoplasm Metastasis 51 Breast Neoplasms 43 Multiple Myeloma 37 Colorectal Neoplasms 34 Pancreatic Neoplasms 26 Ovarian Neoplasms 26 Carcinoma, Renal Cell 26 Triple Negative Breast Neoplasms 25 Myelodysplastic Syndromes 25 Melanoma 25 Leukemia, Lymphocytic, Chronic, B-Cell 25 Lymphoma, Large B-Cell, Diffuse 22 Glioblastoma 22 Urinary Bladder Neoplasms 21 Fallopian Tube Neoplasms 18 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Squamous Cell Carcinoma of Head and Neck 16 Lymphoma 16 Endometrial Neoplasms 16 Carcinoma, Hepatocellular 16 Glioma 15 Burkitt Lymphoma 15 Mouth Neoplasms 14 Lymphoma, Follicular 14 Brain Neoplasms 14 Carcinoma 13

Interventions

Specimen Handling 1 Mastectomy, Subcutaneous 1 Mastectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04541654 2025-08-29

LiFT_UP

Dana-Farber Cancer Institute

Neoplastic Syndromes, Hereditary, Li-Fraumeni Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡